BSB
CRSP icon

Bangor Savings Bank’s CRISPR Therapeutics CRSP Stock Holding History

Bangor Savings Bank’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-255
Closed -$13.8K – 539
2024
Q2 		$13.8K Hold
255
– – ﹤0.01% 387
2024
Q1 		$17.4K Hold
255
– – ﹤0.01% 375
2023
Q4 		$16K Hold
255
– – ﹤0.01% 387
2023
Q3 		$11.6K Hold
255
– – ﹤0.01% 410
2023
Q2 		$14.3K Hold
255
– – ﹤0.01% 407
2023
Q1 		$11.5K Hold
255
– – ﹤0.01% 408
2022
Q4 		$10K Hold
255
– – ﹤0.01% 417
2022
Q3 		$17K Buy
+255
New +$18.5K ﹤0.01% 390

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Bangor Savings Bank's CRSP Position: Q3 2024 in Review

Bangor Savings Bank sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 255 shares — an estimated $13.8K sold.

Bangor Savings Bank first reported a position in CRSP in Q3 2022 and held it in 8 quarters. The position peaked at $17.4K in Q1 2024. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

  • Bangor Savings Bank reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Bangor Savings Bank sold 255 CRISPR Therapeutics shares in Q3 2024, an estimated $13.8K.
  • Bangor Savings Bank first reported a position in CRISPR Therapeutics in Q3 2022 and held it in 8 quarters.
  • Bangor Savings Bank's CRISPR Therapeutics position peaked at $17.4K in Q1 2024.
  • 416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on Bangor Savings Bank's 13F filing for Q3 2024, filed 7 Oct 2024.